ReviewBiology2026
The Programmable Microbiome: Integrative AI and Multi-Omics Frameworks for Precision T2DM Management.
Review in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota is recognized as a programmable metabolic organ that governs systemic homeostasis. Recent advances (2023-2025) have pivoted Type 2 Diabetes Mellitus (T2DM) research from a host-centric perspective toward a failure of bidirectional host-microbe metabolic flux. This review evaluates the molecular mechanisms underpinning this shift, focusing on microbial metabolite signaling, virome-mediated modulation, and the emergence of drug-microbiome interactions as critical therapeutic variables. We highlight the transformative role of AI-guided mapping and digital twin simulations in modeling high-resolution metabolic flux and predicting the stability of engineered microbial consortia. By integrating meta-transcriptomics and epigenomics, we characterize the functional plasticity of the microbiome under therapeutic stress. We argue that framing the microbiota as a programmable infrastructure-integrated with AI analytics and metabolic engineering-enables adaptive, real-time interventions. This synthesis offers a blueprint for transitioning from correlative observations toward precision microbiome engineering to achieve sustained metabolic resilience.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.